The award aims to strengthen the life science sector in the Nordic region by highlighting outstanding leadership at exceptional companies that contribute to promoting innovation, improving healthcare and patient outcomes.

The jury’s motivation for appointing Fredrik Tiberg is: “For his long-term and strategic leadership of Camurus as a leading innovator in long-acting medicines for severe and chronic diseases. His ability to combine scientific excellence with strategic execution over two decades has been crucial in realizing Camurus’ full development and commercial potential, and creating long-term value for both patients and shareholders.”

Camurus’ goal is to develop and make available innovative and potentially life-saving medicines for patients with serious and chronic diseases, such as opioid addiction. Under Fredrik Tiberg’s leadership, the company has evolved from a pure research and development company into a profitable, fast-growing, patient-centric pharmaceutical company with operations in Europe, Australia and the USA, describes the jury.